Department of Nephrology, 2nd Affiliated Hospital, Harbin Medical University, Harbin, China.
Adv Exp Med Biol. 2019;1165:661-670. doi: 10.1007/978-981-13-8871-2_32.
Renal failure is one of the most important causes of mortality and morbidity all over the world. Acute kidney injury (AKI) is a major clinical problem that affects up to 5% of all hospitalized patients. Although the kidney has a remarkable capacity for regeneration after acute injury, the mortality among patients with severe AKI remains dismally high, and in clinical practice, most patients cannot be cured completely and suffer from chronic kidney disease (CKD). Recently, the incidence and prevalence of CKD have increased, largely as a result of the enhanced prevalence of diabetes and obesity. The progressive nature of CKD and the ensuing end-stage renal disease (ESRD) place a substantial burden on global healthcare resources. Currently, dialysis and transplantation remain the only treatment options. Finding new therapeutic methods to fight AKI and CKD remains an ongoing quest. Although the human renal histological structure is complex, stem cell therapies have been applied to repair injured kidneys. The curative effects of mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and nephron progenitor cells (NPCs) on renal repair have also been reported by researchers. This review focuses on stem cell therapy and mechanisms for renal injury repair.
肾衰竭是全世界导致死亡率和发病率的最重要原因之一。急性肾损伤(AKI)是一个主要的临床问题,影响多达 5%的所有住院患者。尽管肾脏在急性损伤后具有显著的再生能力,但重症 AKI 患者的死亡率仍然高得令人沮丧,在临床实践中,大多数患者无法完全治愈,并患有慢性肾脏病(CKD)。最近,CKD 的发病率和流行率有所增加,这在很大程度上是由于糖尿病和肥胖症的患病率增加。CKD 的进行性和随之而来的终末期肾病(ESRD)给全球医疗保健资源带来了巨大负担。目前,透析和移植仍然是唯一的治疗选择。寻找新的治疗方法来对抗 AKI 和 CKD 仍然是一个持续的探索。尽管人类肾脏的组织结构复杂,但干细胞疗法已被应用于修复受损的肾脏。研究人员还报告了间充质干细胞(MSCs)、造血干细胞(HSCs)、诱导多能干细胞(iPSCs)和肾祖细胞(NPCs)对肾脏修复的疗效。本综述重点介绍了干细胞治疗和肾脏损伤修复的机制。